镁基可吸收支架与永久金属西罗莫司洗脱支架在ST段抬高型心肌梗死患者中的比较:MAGSTEMI随机临床试验
MAGSTEMI试验将150例ST段抬高型心肌梗死患者随机分配至镁基可吸收支架(MgBRS)或永久金属西罗莫司洗脱支架(SES),主要终点为12个月时支架/ scaffold段平均管腔直径对硝酸甘油的反应率(≥3%增加)。结果显示MgBRS组主要终点显著更高(56.5% vs 33.8%,P=0.010),但晚期管腔丢失更严重,靶病变血运重建率更高(16.2% vs 5.2%,P=0.030),明确血栓发生率两组相似。
要点
- MgBRS在12个月时血管舒缩反应优于SES,但晚期管腔丢失更显著。
- MgBRS组缺血驱动的靶病变血运重建率更高(16.2% vs 5.2%)。
- 两组明确支架内血栓发生率相似,无血栓安全性担忧。
核心结论
- 在ST段抬高型心肌梗死患者中,MgBRS相比SES在1年时对药物(内皮非依赖及内皮依赖)的血管舒缩反应能力更高。
- 但MgBRS的血管造影疗效较低,靶病变血运重建率更高,且无血栓安全性担忧。
研究设计与样本
- 研究者驱动的多中心、随机、单盲、对照试验,在11个学术中心进行。
- 共随机分配150例ST段抬高型心肌梗死患者(MgBRS组74例,SES组76例),按1:1比例。
- 主要终点为12个月时支架/ scaffold段平均管腔直径对硝酸甘油的反应率(≥3%增加),在 as-treated 人群中比较MgBRS相对于SES的优效性。
- 主要次要终点包括再狭窄的血管造影参数、器械导向复合终点及其各组成部分、器械血栓率。
- 在亚组患者(n=69)中评估了内皮依赖性血管舒缩反应(对乙酰胆碱)。
主要发现
- 1年时主要终点在MgBRS组显著更高(56.5% vs 33.8%;P=0.010)。
- 晚期管腔丢失在SES组显著更低(节段内:0.39±0.49 mm vs 0.02±0.27 mm,P<0.001;器械内:0.61±0.55 mm vs 0.06±0.21 mm,P<0.001)。
- 器械导向复合终点在MgBRS组更高,由缺血驱动的靶病变血运重建率增加所致(12[16.2%] vs 4[5.2%],P=0.030)。
- 明确血栓发生率两组相似(MgBRS组1[1.4%] vs SES组2[2.6%];P=1.0)。
- 器械段内皮功能评估显示,MgBRS组对最大剂量乙酰胆碱的血管收缩反应更明显(-8.3±3.5% vs SES组-2.4±1.3%,P=0.003)。
关键数值与推荐
- 主要终点(12个月支架/ scaffold段平均管腔直径对硝酸甘油反应≥3%增加率):MgBRS组56.5% vs SES组33.8%,P=0.010。
- 晚期管腔丢失(节段内):MgBRS组0.39±0.49 mm vs SES组0.02±0.27 mm,P<0.001。
- 晚期管腔丢失(器械内):MgBRS组0.61±0.55 mm vs SES组0.06±0.21 mm,P<0.001。
- 缺血驱动的靶病变血运重建率:MgBRS组16.2% vs SES组5.2%,P=0.030。
- 明确血栓发生率:MgBRS组1.4% vs SES组2.6%,P=1.0。
临床怎么用
- 对于ST段抬高型心肌梗死患者,MgBRS可提供更好的血管舒缩功能恢复,但需权衡更高的再狭窄和靶病变血运重建风险。
- MgBRS的血栓安全性在1年时与SES相当,但长期结局需进一步研究。
- 临床选择支架时应综合考虑血管功能恢复与血管造影疗效的平衡。
局限性
- 样本量较小(150例),可能影响次要终点的统计效力。
- 随访时间仅1年,无法评估长期临床结局。
- 内皮功能评估仅在亚组(n=69)中进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of poly-l-lactide acid-based bioresorbable scaffolds is limited in daily clinical practice because of safety concerns and lack of physiological benefit. Magnesium-based bioresorbable scaffold (MgBRS) presents a short resorption period (<1 year) and have the potential of being thromboresistant and exhibiting early restoration of vasomotor function. To date, however, no randomized clinical trial has investigated the performance of MgBRS. Therefore, this study aimed to compare the in-stent/scaffold vasomotion between MgBRS and permanent metallic sirolimus-eluting stent (SES) at 12-month follow-up in ST-segment-elevation myocardial infarction patients. METHODS: This investigator-driven, multicenter, randomized, single-blind, controlled trial randomized ST-segment-elevation myocardial infarction patients 1:1 to SES or MgBRS at 11 academic centers. The primary end point was the rate of increase (≥3%) after nitroglycerin in mean lumen diameter of the in-stent/scaffold segment at 12 months with superiority of MgBRS over SES in the as-treated population. The main secondary end points included angiographic parameters of restenosis, device-oriented composite end point, their individual components, and device thrombosis rate. Besides, endothelial-dependent vasomotor response to acetylcholine (ie, endothelial function) was also assessed in a subgroup of patients (n=69). RESULTS: Between June 2017 and June 2018, 150 ST-segment-elevation myocardial infarction patients were randomized (MgBRS, n=74; SES, n=76). At 1 year, the primary end point was significantly higher in the MgBRS arm (56.5% versus 33.8%; P=0.010). Conversely, late lumen loss was significantly lower in the SES group (in-segment: 0.39±0.49mm versus 0.02±0.27mm, P<0.001; in-device: 0.61±0.55mm versus 0.06±0.21mm; P<0.001). The device-oriented composite end point was higher in the MgBRS arm driven by an increase in ischemia-driven target lesion revascularization rate (12[16.2%] versus 4[5.2%], P=0.030). Definite thrombosis rate was similar between groups (1[1.4%] in the MgBRS arm versus 2[2.6%] in the SES group; P=1.0). Endothelial function assessment at device segment evidenced a more pronounced vasoconstrictive response to maximal dose of acetylcholine in the MgBRS arm (-8.3±3.5% versus -2.4±1.3% in the SES group, P=0.003). CONCLUSIONS: When compared to SES, MgBRS demonstrated a higher capacity of vasomotor response to pharmacological agents (either endothelium-independent or endothelium-dependent) at 1 year. However, MgBRS was associated with a lower angiographic efficacy, a higher rate of target lesion revascularization, without thrombotic safety concerns. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03234348.
引用
- Sabaté M, Alfonso F, Cequier A, et al. Magnesium-Based Resorbable Scaffold Versus Permanent Metallic Sirolimus-Eluting Stent in Patients With ST-Segment Elevation Myocardial Infarction: The MAGSTEMI Randomized Clinical Trial. Circulation. 2019. PMID: 31553204. doi:10.1161/CIRCULATIONAHA.119.043467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。